CClinicalTrials.gg
CompletedNCT03072264Updated Feb 27, 2019

Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder

An interventional study of Body in Mind Training (BMT) and Fluoxetine in Generalized Anxiety Disorder, sponsored by Hospital de Clinicas de Porto Alegre. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-27.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2016, registered Jan 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The literature suggests that Mindfulness Based Intervention may be effective in the treatment of anxiety symptoms. The objective of this study is to compare the clinical effectiveness of a Mindfulness Based Intervention - the Mind in Body Training (MBT) - with a selective serotonin reuptake inhibitor (Fluoxetine) and an active control group (Quality of Life) through different biological and clinical outcomes, as well as evaluate some possible mechanisms of treatment response. Methods: it is a three armed randomized, controlled clinical trial. Participants with General Anxiety Disorder will be recruited. A community sample of 192 participants will be randomly allocated to the MBT, Fluoxetine or Quality of Life Group. Instruments measuring anxiety, worry and meta-worry symptoms, quality of life, acceptance and self-compassion, mindfulness, rumination and emotion regulation will be applied. The patients will be submitted to Error Related Negativity (ERN) and Heart Rate Variability (HRV) measures. The primary outcome is the effectiveness of MBT compared with Fluoxetine and Quality of Life Group in symptomatic outcomes. The secondary outcome are the effectiveness os these interventions in emotional regulation process and biological measures (ERN and HRV), and the evaluation of BMT mechanisms through possible mediation of treatment response for emotional processes like mindfulness, acceptance and self-compassion, biological changes (ERN and HRV), and metacognition.

Read the detailed description

Generalized Anxiety Disorder (GAD) is the most prevalent Anxiety Disorder after Specific Phobia. It is characterized by persistent and excessive anxiety and worry about different domains of life that is difficult to control, and the individuals can experience physical symptoms, like restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. Also, GAD is one of the most common mental disorders in primary care settings, and it is associated with increased use of health care resources and disability, functional impairment, psychiatric and medical comorbidities.

Despite its prevalence and impairment, this disorder is under-recognized, and less than one-third of patients are adequately treated. The literature demonstrates that either psychotropic medications or cognitive behavior therapy (CBT) appear to be effective for treating GAD. However, a substantial number of patients do not respond to initial treatment, and, although the response rates are inconsistent across studies, only 38% of the treated patients have a remission after five years. Moreover, GAD is usually a chronic disorder with a waxing and waning course, requiring a long-term treatment.

In relation to some biological mechanisms in GAD, some studies report an enhanced Error-Related Negativity (ERN) and a lower Heart Rate Variability (HRV) in GAD patients. The first biological marker could be associated with anxious apprehension and the main findings are found in GAD while the second one reflects a reduction in parasympathetic modulation. On the other hand, it is already known that mindfulness meditation practice is associated with increase in autonomic regulation by stimulating the parasympathetic system. In relation to cognitive factors, the literature demonstrates that GAD patients have a higher level of experiential avoidance and distress about emotions, more negative believes about worry and meta-worry.

Mindfulness is a practice developed to foster self-regulation. Historically, the mindfulness exercises used in clinical protocols are linked with the Buddhist framework in which it is a means to alleviate suffering and cultivate compassion. In the West, the role of mindfulness in health promotion has been the target of studies since the 70s and it has been incorporated in cognitive-behavioural treatments. The Body in mind training (BMT) is a treatment protocol that focuses on movement and motor system as a tool for mindfulness practice. More than three decades of studies have shown the positive effects of mindfulness based interventions (MBIs) in both mental and physical health and quality of life either in general population or clinical populations. Also, MBIs seem to be effective and a lasting alternative to treat anxiety. In relation to GAD, some studies have shown that MBI's are effective, but, in generally, they are limited by the small sample size or the use of waiting list control instead of an active control group.

So, the objective of this research is to evaluate the effectiveness of BMT intervention and compared to Fluoxetine and a Quality of Life Group in the treatment of GAD patients. Also, we intend to evaluate some biological and cognitive mechanisms of these different treatments through mediators analysis.

It is a single blind Randomized Controlled Trial with three arms of treatments. The individuals will be recruited in the community. Generalized Anxiety patients (according to Mini-International Neuropsychiatric Interview) will be randomly allocated (in a 1:1:1 ratio) to receive either antidepressant: BMT: Control Group. Research assessors will be masked. Because of the nature of the interventions, patients and clinicians will be aware of treatment allocation. The duration of the treatments is 8 weeks.

Before, in the week 5, and after the interventions, participants will be assessed with the Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression (CGI), Anxiety Sensitivity Index (ASI), Penn State Worry Questionnaire (PSWQ), Difficulties in Emotion Regulation Scale (DERS), Five Facet Mindfulness Questionnaire (FFMQ), Self-Compassion Scale (SCS), Action and Acceptance Questionnaire (AAQ), Ruminative Response Scale (RRS), Metacognition Questionnaire (MCQ-30), Meta-worry Questionnaire (MWQ), WHOQOL-Bref. Also, before the interventions, participants will answer the Early Life Experiences Scale (ELES) and Early Memories of Warmth and Safeness Scale (EMWSS). The HRV and ERN will be assessed before and after the interventions.

02

Conditions studied

  • Generalized Anxiety Disorder

Browse trials for

Keywords

  • Generalized Anxiety Disorder, GAD, mindfulness, anxiety
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 200 is above the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Hospital de Clinicas de Porto Alegre is the lead sponsor of 450 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • More than 18 years old;
  • Primary Generalized Anxiety Disorder (GAD) according to M.I.N.I;
  • Possibility to attend the Hospital every week during 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Current psychopharmacological or psychotherapeutic treatment for GAD;
  • Previous no response treatment with fluoxetine for GAD;
  • Bipolar Disorder, Psychotic Disorder, Substance Use Disorder (except tobacco) in the last 6 months or Suicidal Ideation in the last 6 months (M.I.N.I);
  • Hamilton Depression Scale (HAM-D) ≥23;
  • Any contraindication to fluoxetine use;
  • Clinical instability or immobility;
  • Pregnancy or lactation;
  • Antisocial Personality Disorder;
  • Eating Disorder.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Body in Mind Training (BMT)

    This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.

    Behavioral: Body in Mind Training (BMT)

  • Active comparator
    Medication

    In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.

    Drug: Fluoxetine

  • Active comparator
    Quality of Life Group

    This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.

    Behavioral: Quality of Life Group

Interventions

  • BehavioralBody in Mind Training (BMT)

    Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.

    Also known as: Mindfulness Based Intervention

  • DrugFluoxetine

    In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.

    Also known as: Control Group

  • BehavioralQuality of Life Group

    Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Penn State Worry Questionnaire (PSWQ) Score

    Efficacy Assessment

    Time frame: Baseline , 8 weeks

  2. Mean Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score

    Efficacy Assessment

    Time frame: Baseline , 8 weeks

Secondary outcomes

  1. Mean Change From Baseline in Heart Rate variability (HRV)

    Biological Efficacy Assessment 1

    Time frame: Baseline , 8 weeks

  2. Mean Change From Baseline in Error-Related Negativity (ERN)

    Biological Efficacy Assessment 2

    Time frame: Baseline , 8 weeks

  3. Mean Change From Baseline in Quality of Life (WHOQOL) Scores

    Efficacy Assessment in Quality of Life

    Time frame: Baseline , 8 weeks

07

Study locations

1 site
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, RS 90035-903, Brazil
08

References and documents

Publications

  • Costa MA, Goncalves FG, Tatton-Ramos T, Fonseca NKOD, Schwinn JK, Alves SG, Salum GA, Manfro GG. A Three-Arm Randomized Clinical Trial Comparing the Efficacy of a Mindfulness-Based Intervention with an Active Comparison Group and Fluoxetine Treatment for Adults with Generalized Anxiety Disorder. Psychother Psychosom. 2021;90(4):269-279. doi: 10.1159/000511880. Epub 2020 Dec 15. PubMed 33321509 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03072264
Lead sponsor
Hospital de Clinicas de Porto Alegre
Responsible party
Sponsor
First posted
Mar 7, 2017
Start date
Oct 2016
Primary completion
Dec 2018
Completion
Dec 2018
Last update
Feb 27, 2019

Study contacts

Gisele Gus Manfro
study director · Federal University of Rio Grande do Sul

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion